FDA Lifts Clinical Hold on GH001, Paving Way for Global Phase 3 in Treatment-Resistant Depression
GHRS has more than doubled off its 52-week low of $6.95 on elevated volume (2.9× avg).
Summary
GH Research announced the FDA has lifted the clinical hold on its lead drug candidate, GH001, for treatment-resistant depression, clearing the path for global Phase 3 trials to begin in 2026.
Key Events · Product Development and Regulatory · GHRS
-
FDA Clinical Hold Lifted
The U.S. Food and Drug Administration (FDA) has removed the clinical hold on GH001's Investigational New Drug (IND) application.
-
Path to Global Phase 3
This clearance enables U.S. subject enrollment and allows GH Research to proceed with its global pivotal Phase 3 program for GH001 in treatment-resistant depression (TRD), targeted for initiation in 2026.
-
Strong Phase 2b Data
Previously reported Phase 2b trial (GH001-TRD-201) showed GH001 met its primary endpoint with a -15.5 point placebo-adjusted MADRS reduction on Day 8 (p<0.0001) and achieved 57.5% ultra-rapid remission on Day 8.
-
Favorable Profile
GH001 demonstrated 73% remission at 6 months with infrequent dosing, a short psychoactive experience (median ~11 minutes), no required psychotherapy, and a favorable safety profile with no serious treatment-related adverse events.
Analysis · GHRS · Life Sciences
The U.S. FDA's decision to lift the clinical hold on GH Research's lead candidate, GH001, is a significant positive development. This regulatory clearance removes a major hurdle, enabling U.S. patient enrollment and allowing the company to advance GH001 into a global pivotal Phase 3 program for treatment-resistant depression (TRD) in 2026. The company's previously reported Phase 2b data for GH001 demonstrated strong efficacy, ultra-rapid remission, and a favorable safety profile, which, if replicated in Phase 3, could position GH001 as a highly competitive and potentially practice-changing treatment option in the TRD market. Investors should monitor the initiation and progress of the Phase 3 trials.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GHRS was trading at $15.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $821.3M. The 52-week trading range was $6.95 to $20.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.